StreetInsider.com News Articles

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

Bayer today announced that new investigational data from KERENDIA’s Phase III clinical trial program will be presented in scientific sessions at the 63rd European Renal Association (ERA) Congress taking place June 3-6, 2026, in Glasgow, Scotland. Presentations include:

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026

Tue, 02 Jun 2026 08:00:00 -0400

Presentations also include the INFINITY pooled analysis of KERENDIA® (finerenone) across diabetic and non-diabetic chronic kidney disease.

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer

Summary

The first full data results from the global FIND‑CKD (NCT05047263) study evaluating the addition of KERENDIA to standard of care in adults with non-diabetic chronic kidney disease (nd-CKD).
- A prespecified subgroup analysis of FIND-CKD that evaluated

ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

Sat, 30 May 2026 17:24:00 -0400

Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD) by 24 weeks, with a median maximal cognitive decline of -15.8% for NUBEQA versus -36.1% with enzalutamide (p=0.009) in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) or metastatic castration-sensitive prostate cancer (mCSPC) in a trial conducted by Alliance Foundation Trials
All patients who switched treatment had been randomized to enzalutamide and later moved to NUBEQA, driven predominantly by objective or subjective cognitive decline
Primary results from the Phase II ARACOG trial were presented as

ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

Sat, 30 May 2026 17:24:00 -0400

Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD) by 24 weeks, with a median maximal cognitive decline of -15.8% for NUBEQA versus -36.1% with enzalutamide (p=0.009) in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) or metastatic castration-sensitive prostate cancer (mCSPC) in a trial conducted by Alliance Foundation Trials
All patients who switched treatment had been randomized to enzalutamide and later moved to NUBEQA, driven predominantly by objective or subjective cognitive decline
Primary results from the Phase II ARACOG trial were presented as

ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

Sat, 30 May 2026 17:24:00 -0400

Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD) by 24 weeks, with a median maximal cognitive decline of -15.8% for NUBEQA versus -36.1% with enzalutamide (p=0.009) in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) or metastatic castration-sensitive prostate cancer (mCSPC) in a trial conducted by Alliance Foundation Trials
All patients who switched treatment had been randomized to enzalutamide and later moved to NUBEQA, driven predominantly by objective or subjective cognitive decline
Primary results from the Phase II ARACOG trial were presented as